Statistics in Medicine

• 

  Publication Venue For

  • Dynamic prediction of Alzheimer's disease progression using features of multiple longitudinal outcomes and time-to-event data. 2019
  • Simultaneous record linkage and causal inference with propensity score subclassification..  37:3533-3546. 2018
  • Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks..  37:1389-1401. 2018
  • Accommodating the ecological fallacy in disease mapping in the absence of individual exposures..  36:4930-4942. 2017
  • On assessing bioequivalence and interchangeability between generics based on indirect comparisons..  36:2978-2993. 2017
  • Bayesian multinomial probit modeling of daily windows of susceptibility for maternal PM2.5 exposure and congenital heart defects..  35:2786-2801. 2016
  • Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis..  34:3399-3414. 2015
  • Scan-stratified case-control sampling for modeling blood-brain barrier integrity in multiple sclerosis..  34:2872-2880. 2015
  • A marginalized zero-inflated Poisson regression model with overall exposure effects..  33:5151-5165. 2014
  • Imputation of confidential data sets with spatial locations using disease mapping models..  33:1928-1945. 2014
  • Correction to How to interpret a small increase in AUC with an additional risk prediction marker: Decision analysis comes through [Statist. Med. (2015) 33, 22, 3946-3959] DOI: 10.1002/sim.6195.  34:900. 2014
  • A latent factor linear mixed model for high-dimensional longitudinal data analysis..  32:4229-4239. 2013
  • Propensity score weighting with multilevel data..  32:3373-3387. 2013
  • An information criterion for marginal structural models..  32:1383-1393. 2013
  • Phase II clinical trials with time-to-event endpoints: Optimal two-stage designs with one-sample log-rank test 2013
  • A spatio-temporal absorbing state model for disease and syndromic surveillance..  31:2123-2136. 2012
  • Sensitivity analysis for unmeasured confounding in principal stratification settings with binary variables..  31:949-962. 2012
  • Correction: Evaluation metrics for biostatistical and epidemiological collaborations.  31:600. 2012
  • Authors' reply.  31:96-97. 2012
  • A min-max combination of biomarkers to improve diagnostic accuracy.  30:3266. 2011
  • The end of the beginning: A commentary on 'Evaluation metrics for biostatistical and epidemiological collaborations': A rejoinder.  30:2783-2784. 2011
  • Hierarchical spatial modeling of uncertainty in air pollution and birth weight study..  30:2187-2198. 2011
  • Estimating propensity scores with missing covariate data using general location mixture models..  30:627-641. 2011
  • Erratum: A rank-based sample size method for multiple outcomes in clinical trials.  30:597. 2011
  • Using Testlet Response Theory to analyze data from a survey of attitude change among breast cancer survivors..  29:2028-2044. 2010
  • Joint Bayesian analysis of birthweight and censored gestational age using finite mixture models..  29:1710-1723. 2010
  • A bivariate survival model with compound Poisson frailty..  29:275-283. 2010
  • A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data..  29:75-85. 2010
  • Response to ‘Net reclassification improvement and decision theory’ by Vickerset al..  28:526-528. 2009
  • Semiparametric Bayesian modeling of random genetic effects in family-based association studies..  28:113-139. 2009
  • 'Smooth' inference for survival functions with arbitrarily censored data..  27:5421-5439. 2008
  • Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology..  27:5525-5555. 2008
  • Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach..  27:4658-4677. 2008
  • A distribution-free test of constant mean in linear mixed effects models..  27:3833-3846. 2008
  • Estimation of propensity scores using generalized additive models..  27:3805-3816. 2008
  • Sample size calculation for the weighted rank statistics with paired survival data..  27:3350-3365. 2008
  • A rank-based sample size method for multiple outcomes in clinical trials..  27:3084-3104. 2008
  • Joint modeling of sensitivity and specificity..  27:1745-1761. 2008
  • Randomized phase II trials with a prospective control..  27:568-583. 2008
  • Comments on 'Integrated discrimination and net reclassification improvements - Practical advice'.  27:207-212. 2008
  • Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond..  27:157-172. 2008
  • Relative quantification based on logistic models for individual polymerase chain reactions..  26:5596-5611. 2007
  • Morphometric analysis for early detection of changes in cellular structure in a toxicological experiment..  26:5253-5266. 2007
  • A correlated frailty model with long-term survivors for estimating the heritability of breast cancer..  26:3722-3734. 2007
  • Analysis on binary responses with ordered covariates and missing data..  26:3443-3458. 2007
  • Bayesian methods for searching for optimal rules for timing intercourse to achieve pregnancy..  26:1920-1936. 2007
  • Stability analysis for drugs with multiple active ingredients..  26:1512-1517. 2007
  • A multivariate test for population bioequivalence..  26:1208-1223. 2007
  • Bivariate random effect model using skew-normal distribution with application to HIV-RNA.  26:1255-1267. 2007
  • Choice of time scale and its effect on significance of predictors in longitudinal studies..  26:1343-1359. 2007
  • Bivariate random effect model using skew-normal distribution with application to HIV-RNA..  26:1255-1267. 2007
  • Performance assessment for radiologists interpreting screening mammography..  26:1532-1551. 2007
  • Inference for case-control studies when exposure status is both informatively missing and misclassified..  25:4065-4080. 2006
  • Bayesian semi-parametric ROC analysis..  25:3905-3928. 2006
  • Estimating measures of diagnostic accuracy when some covariate information is missing..  25:2981-2993. 2006
  • Interval estimation for treatment effects using propensity score matching..  25:2230-2256. 2006
  • Author's reply [4].  25:1437-1438. 2006
  • On non-inferiority margin and statistical tests in active control trials..  25:1101-1113. 2006
  • Rank tests for clustered survival data when dependent subunits are randomized..  25:361-373. 2006
  • Examining accuracy of screening mammography using an event order model..  25:267-283. 2006
  • Assay validation for left-censored data..  24:3347-3360. 2005
  • A multiple testing procedure to associate gene expression levels with survival..  24:3077-3088. 2005
  • Sample size for a two-group comparison of repeated binary measurements using GEE..  24:2583-2596. 2005
  • Statistical inference for cancer trials with treatment switching..  24:1783-1790. 2005
  • Assessing intra, inter and total agreement with replicated readings..  24:1371-1384. 2005
  • A practical approach for comparing means of two groups without equal variance assumption: H. Wang and S. Chow, Statistics in Medicine 2002; 21:3137-3151..  24:817-818. 2005
  • Analysis of clinical data with breached blindness: by Shein-Chung Chow and Jun Shao Statistics in Medicine 2004; 23:1185-1193..  24:819-821. 2005
  • Strength of accumulating evidence and data monitoring committee decision making..  23:2659-2672. 2004
  • Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation..  23:2109-2123. 2004
  • Sample size determination for comparing several survival curves with unequal allocations..  23:1793-1815. 2004
  • Odds ratios for a continuous outcome variable without dichotomizing..  23:1843-1860. 2004
  • Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?.  23:1503-1505. 2004
  • Analysis of clinical data with breached blindness..  23:1185-1193. 2004
  • On the estimation of the binomial probability in multistage clinical trials..  23:881-896. 2004
  • Admissible two-stage designs for phase II cancer clinical trials..  23:561-569. 2004
  • Growth velocity assessment in paediatric AIDS: smoothing, penalized quantile regression and the definition of growth failure..  23:509-526. 2004
  • The heritability of cause-specific mortality: a correlated gamma-frailty model applied to mortality due to respiratory diseases in Danish twins born 1870-1930..  22:3873-3887. 2003
  • ROC methodology within a monitoring framework..  22:3473-3488. 2003
  • Comparing linear and nonlinear mixed model approaches to cosinor analysis.  22:3195-3211. 2003
  • A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present..  22:2711-2721. 2003
  • Evaluating medical diagnostic tests at the subunit level in the presence of verification bias..  22:2161-2176. 2003
  • Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes..  22:1943-1954. 2003
  • Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen..  22:1457-1464. 2003
  • Sample size estimation for GEE method for comparing slopes in repeated measurements data..  22:1305-1315. 2003
  • Missing data in the 2 x 2 table: patterns and likelihood-based analysis for cross-sectional studies with supplemental sampling..  22:517-534. 2003
  • A parametric model for long-term follow-up data from phase III breast cancer clinical trials..  22:339-352. 2003
  • In vitro bioequivalence testing..  22:55-68. 2003
  • A practical approach for comparing means of two groups without equal variance assumption..  21:3137-3151. 2002
  • The ebb and flow of the NHS waiting list: how do recruitment and admission affect event-based measures of the length of 'time-to-admission'?.  21:2991-3009. 2002
  • Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?.  21:2889-2897. 2002
  • Industry perspectives on ICH guidelines..  21:2949-2957. 2002
  • A multistate model for the genetic analysis of the ageing process..  21:2511-2526. 2002
  • Reproducibility probability in clinical trials..  21:1727-1742. 2002
  • Individual bioequivalence testing under 2x3 designs..  21:629-648. 2002
  • Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head..  21:371-387. 2002
  • The impact of the international guideline entitled Statistical Principles for Clinical Trials (ICH E9)..  20:2549-2560. 2001
  • Using observational data to estimate prognosis: an example using a coronary artery disease registry..  20:2505-2532. 2001
  • Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies..  20:2489-2504. 2001
  • Evaluation of an adjusted chi-square statistic as applied to observational studies involving clustered binary data..  20:2149-2161. 2001
  • Sample size calculations for clustered binary data..  20:1971-1982. 2001
  • Two-phase shelf-life estimation..  20:1239-1248. 2001
  • Tests for 2 x K contingency tables with clustered ordered categorical data..  20:785-794. 2001
  • Assessing human fertility using several markers of ovulation..  20:965-978. 2001
  • Bayesian analyses of longitudinal binary data using Markov regression models of unknown order..  20:755-770. 2001
  • Detecting treatment-by-centre interaction in multi-centre clinical trials..  20:193-213. 2001
  • Strategic use of statistical thinking in drug development..  19:3211-3217. 2000
  • A small sample confidence interval approach to assess individual bioequivalence..  19:2885-2897. 2000
  • An individual bioequivalence criterion: regulatory considerations..  19:2821-2842. 2000
  • Preface. Bioequilavence measures..  19:2719. 2000
  • The bootstrap procedure in individual bioequivalence..  19:2741-2754. 2000
  • First steps in analysing NHS waiting times: avoiding the 'stationary and closed population' fallacy..  19:2037-2051. 2000
  • Modelling covariance structure in the analysis of repeated measures data..  19:1793-1819. 2000
  • On statistical analysis for placebo-challenging designs in clinical trials..  19:1029-1037. 2000
  • Generalized treatment effects for clinical trials..  19:887-899. 2000
  • Sample size to test for interaction between a specific exposure and a second risk factor in a pair-matched case-control study..  19:923-935. 2000
  • Comparison of diagnostic markers with repeated measurements: a non-parametric ROC curve approach..  19:511-523. 2000
  • Prognostic models based on literature and individual patient data in logistic regression analysis..  19:141-160. 2000
  • Accounting for unreported and missing intercourse in human fertility studies.  19:665-679. 2000
  • The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials..  18:3435-3451. 1999
  • Evaluating the exposure and disease relationship with adjustment for different types of exposure misclassification: a regression approach..  18:2795-2808. 1999
  • Testing proportionality in the proportional odds model fitted with GEE..  18:1419-1433. 1999
  • A hierarchical Bayesian approach to age-specific back-calculation of cancer incidence rates..  18:919-933. 1999
  • A regression model for multivariate random length data..  18:199-211. 1999
  • Combining classification trees using MLE.  18:727-740. 1999
  • Age-period-cohort analysis of chronic disease rates. I: Modelling approach..  17:1305-1323. 1998
  • Age-period-cohort models of chronic disease rates. II: Graphical approaches..  17:1325-1339. 1998
  • A generalized F mixture model for cure rate estimation..  17:813-830. 1998
  • Age at any birth and breast cancer risk..  17:431-445. 1998
  • Comparing risk-adjustment methods for provider profiling..  16:2645-2664. 1997
  • Discriminant analysis using the unweighted sum of binary variables: a comparison of model selection methods..  16:2679-2700. 1997
  • Estimating correlations from epidemiological data in the presence of measurement error..  16:2177-2189. 1997
  • Bayesian inference in two-phase prevalence studies..  16:1121-1133. 1997
  • Statistical methods for two-sequence three-period cross-over designs with incomplete data..  16:1031-1039. 1997
  • A parametric approach to population bioequivalence..  16:441-454. 1997
  • The impact of patient compliance on drug concentration profile in multiple doses..  15:659-669. 1996
  • Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.  15:361-387. 1996
  • Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors..  15:361-387. 1996
  • Polynomials with asymptotes for longitudinal data..  15:61-74. 1996
  • The impact of patient compliance on drug concentration profile in multiple doses.  15:659-669. 1996
  • A statistic for comparing two correlated markers which are prognostic for time to an event..  14:2217-2225. 1995
  • The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables..  14:2119-2129. 1995
  • Prediction and decision making using Bayesian hierarchical models..  14:2173-2190. 1995
  • Multi-state models and diabetic retinopathy.  14:1975-1983. 1995
  • Smoothing splines for longitudinal data.  14:1235-1248. 1995
  • Non-parametric estimation for the difference or ratio of median failure times for paired observations..  14:275-281. 1995
  • A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments..  13:2289-2309. 1994
  • ON THE EFFICACY OF THE RANK TRANSFORMATION IN STEPWISE LOGISTIC AND DISCRIMINANT-ANALYSIS - REPLY.  13:1794-1795. 1994
  • Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer..  13:1313-1327. 1994
  • The case against independent monitoring committees..  13:1411-1414. 1994
  • Two-stage sampling in pharmaceutical applications..  12:1999-2008. 1993
  • A survey of monitoring practices in cancer clinical trials..  12:435-450. 1993
  • Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations..  12:471-479. 1993
  • Discussion: Stephen George, a survey of monitoring practices in cancer clinical trials: Stephanie Green and John Crowley, data monitoring committees for Southwest Oncology Group clinical trials.  12:457-459. 1993
  • On the efficacy of the rank transformation in stepwise logistic and discriminant analysis..  12:143-151. 1993
  • Analysing the relationship between change in a risk factor and risk of disease..  11:783-797. 1992
  • Application of empirical Bayes inference to estimation of rate of change in the presence of informative right censoring..  11:621-631. 1992
  • Test for batch-to-batch variation in stability analysis..  11:269-270. 1992
  • A comparison of several tests for censored paired data..  11:193-208. 1992
  • Correction: Outlier detection in bioavailability/bioequivalence studies (Statistics in Medicine (1990) 9 (549-558)).  11:425. 1992
  • On the estimation of total variability in assay validation..  10:1543-1553. 1991
  • Analyses of black and white differentials in the age trajectory of mortality in two closed cohort studies..  10:1043-1059. 1991
  • Methods for the analysis and assessment of clinical databases: the clinician's perspective..  10:617-628. 1991
  • Outlier detection in bioavailability/bioequivalence studies..  9:549-558. 1990
  • Test for batch-to-batch variation in stability analysis..  8:883-890. 1989
  • Beyond sensitivity, specificity and statistical independence.  7:1289-1295. 1988
  • Commentary. Response to Dr Halperin on ‘models of the interaction of mortality and the evolution of risk factor distribution: A general stochastic process formulation’.  7:293-295. 1988
  • Estimating hidden morbidity via its effect on mortality and disability..  7:325-336. 1988
  • Models of the interaction of mortality and the evolution of risk factor distribution: a general stochastic process formulation..  7:239-256. 1988
  • Age, period and cohort models: the use of individual records..  5:527-538. 1986
  • The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model..  4:39-46. 1985
  • Tying clinical research to patient care by use of an observational database..  3:375-387. 1984
  • Regression modelling strategies for improved prognostic prediction..  3:143-152. 1984
  • Strategies for analysing ecological health data: models of the biological risk of individuals..  1:163-181. 1982
  • Mantel-Haenszel statistics and direct standardization..  1:37-39. 1982
  • Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view 1993